Kali Therapeutics, a clinical-stage biotech founded in June 2024 by former Harbour BioMed executive Dr. Weihao Xu, has filed its IPO prospectus shortly after securing a landmark licensing agreement with Sanofi for KT501, a novel IgG-like tri-specific T cell engager targeting CD3, CD19, and BCMA. The deal includes $180 million upfront and up to $1.05 billion in milestones, with KT501 currently in Phase I trials for rheumatoid arthritis. Leveraging its proprietary CD3-masking platform, KT501 demonstrates potent B-cell depletion with minimal cytokine release in preclinical studies, positioning it as a potential best-in-class therapy for B-cell-mediated autoimmune diseases.

The 2026 Government Work Report officially lists biopharmaceuticals as an emerging pillar industry and includes brain-computer interface (BCI) for the first time among key future industries, signaling strong national policy support. The report highlights recent industry developments, including regulatory approvals for innovative drugs such as rovatinib tablets (China Biopharma), pirtobrutinib (Innovent Bio), and damilertinib mesylate tablets (Hansoh Pharma), as well as global licensing deals like Teclison’s ATG-201 with UCB. Despite a 4.72% weekly decline in the SW Pharma & Biotech Index, the sector maintains a TTM PE ratio of 48.07x and a 238% valuation premium over CSI 300. Analysts remain optimistic on innovation-driven opportunities in biopharma, CXO, and life science tools, alongside thematic catalysts from BCI and AI applications.

On March 4, 2026, China Biopharmaceutical Limited (HKEX: 1177) announced a global exclusive licensing agreement between its subsidiary, Chia Tai Tianqing Pharmaceutical Group, and a wholly owned affiliate of Sanofi S.A. for rovadicitinib, a first-in-class oral JAK/ROCK dual inhibitor. Under the deal, China Biopharmaceutical will receive an upfront payment of $135 million and is eligible for up to $1.395 billion in development, regulatory, and sales milestone payments, plus double-digit tiered royalties on net sales. Rovadicitinib was approved by China’s NMPA in February 2026 for first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. It also shows breakthrough potential in chronic graft-versus-host disease (cGVHD), with Phase III trials ongoing in China and Ib/IIa data published in Blood demonstrating superior 12-month failure-free survival compared to existing therapies.

Since January 2026, multiple pharmaceutical companies worldwide have announced extended or enhanced partnerships to accelerate R&D and commercialization, share risks, and secure competitive advantages. Key collaborations include Syngene International and Bristol Myers Squibb extending their strategic alliance through 2035 with full lifecycle drug development coverage; Kelun-Biotech renewing its R&D supply framework agreement with China Resources Kelun until end-2028 to leverage distribution networks and boost market recognition; AstraZeneca and YaoYiGou deepening cooperation in omnichannel digital empowerment, market expansion, and end-to-end drug traceability; and Earendil Labs (a subsidiary of HuaShen Bio) partnering again with Sanofi to apply its AI-driven drug discovery platform to autoimmune and inflammatory disease programs, with Sanofi leading global development and commercialization of resulting bispecific antibody candidates.

Earendil Labs, an AI-driven biotech firm, has entered into a strategic partnership with Sanofi to leverage its proprietary drug discovery platform for multiple autoimmune and inflammatory disease programs. Under the agreement, Sanofi will lead global development and commercialization of resulting bispecific antibody candidates, while Earendil is eligible to receive up to $160 million in upfront and near-term milestone payments, with potential total deal value reaching $2.56 billion, plus tiered royalties up to low double-digit percentages on net sales. The collaboration underscores Earendil’s commitment to advancing next-generation therapies with first-in-class or best-in-class potential through integrated AI modeling and high-throughput experimental validation.

As one of the most popular sections in previous CIIEs, the Medical Equipment and Healthcare Products exhibition area moved to Halls 1.1, 1.2, and 2.2 this year. The world’s top ten medical device giants and 12 Fortune Global 500 pharmaceutical companies gathered in this expansive space exceeding 70,000 square meters.

On November 5, Sanofi announced that its innovative drug Cablivi® (caplacizumab) has been approved by China's National Medical Products Administration (NMPA) for use in combination with plasma exchange and immunosuppressive therapy to treat adults and adolescents aged 12 years and older weighing at least 40 kg with acquired thrombotic thrombocytopenic purpura (aTTP), also known as immune-mediated TTP (iTTP). The approval, granted just six months after application submission, was accelerated under China’s priority review pathway for urgently needed rare disease therapies. The drug was showcased on the same day at the China International Import Expo.

On October 27, Medidata, a Dassault Systèmes company and provider of clinical trial solutions for the life sciences industry, announced an extension of its collaboration with Sanofi in clinical research. The expanded partnership will drive Sanofi’s adoption of Medidata’s patient experience, data experience, and study experience solutions to enhance innovation in clinical trials and accelerate the delivery of new therapies to market.

On October 22, Sanofi announced that its investigational monoclonal antibody SAR446523 received its first clinical approval in China from the Center for Drug Evaluation (CDE) for the treatment of relapsed or refractory multiple myeloma (R/R MM). SAR446523 is the world’s first GPRC5D-targeting monoclonal antibody to enter clinical development. Designed as an IgG1-based antibody with an engineered Fc domain to enhance antibody-dependent cellular cytotoxicity (ADCC), it targets GPRC5D—a protein highly expressed on malignant plasma cells in multiple myeloma but with limited expression in healthy tissues. The U.S. FDA granted SAR446523 orphan drug designation for multiple myeloma in July. A Phase I clinical trial (NCT06630806) is ongoing overseas to evaluate the safety, anti-tumor activity, pharmacokinetics, and pharmacodynamics of subcutaneous SAR446523 in R/R MM patients. Among the 37 active global pipelines targeting GPRC5D—including CAR-Ts, bispecifics, trispecifics, and monoclonal antibodies—SAR446523 is the only GPRC5D monoclonal antibody currently in clinical trials.

On October 22, South San Francisco-based clinical-stage biotech Electra Therapeutics announced the completion of an oversubscribed $183 million Series C financing led by Nextech and EQT Life Sciences, with participation from new investors including Sanofi, HBM Healthcare Investments, and Mubadala Capital, as well as existing investors. The proceeds will support global pivotal Phase 2/3 trials of ELA026, a SIRP-targeted monoclonal antibody, in secondary hemophagocytic lymphohistiocytosis (sHLH)—a highly fatal inflammatory condition—and advance its second SIRP-targeted candidate, ELA822, into clinical development for T cell-mediated autoimmune diseases. ELA026 demonstrated 100% overall survival at 8 weeks in cancer-associated sHLH patients in Phase 1b, significantly outperforming historical benchmarks.